ClinicalTrials.gg
CompletedNCT01767467Updated Jun 6, 2018Results posted

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

A Phase 3 interventional study of Herpes zoster vaccine (GSK 1437173A) and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 86 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
568
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.

Enrollment
17th of 37
568 · median 450
Started
2013
with 7 others
Phase 3
25 of 44
none open now
Registered
15th of 44
by date

Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 17th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 15th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Herpes Zoster by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.

Read the detailed description

Amendment to protocol posting:

Increase in sample size, update of country/region-specific information (Sections 5, 6 and 9).

Promotion of secondary to primary objective; related update of primary and secondary outcome measures (Sections 4 and 7).

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Immunogenicity
  • Safety
  • Herpes zoster
  • Vaccination
  • Haematologic malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes can and will comply with the requirements of the protocol.
  • Written obtained from the subject.
  • A male or female, aged 18 years or older at the time of study entry.
  • Subject who has been diagnosed with one or more haematologic prior to the first vaccination and who is receiving, is scheduled to receive or has just finished cancer therapy to treat this condition.
  • greater than or equal to 12 months, as assessed by the investigator.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled inthe study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Subject diagnosed with chronic lymphocytic leukaemia (CLL) who is receiving only oral cancer therapy (subject receiving intra-venous cancer therapy for CLL or intra-venous cancer therapy in combination with oral therapy may be enrolled).
  • Subject receiving radiotherapy alone as treatment for his/her haematologic .
  • Planned haematopoietic stem cell transplant (HCT) during the study period. (If a HCT occurred prior to enrolment in the study, the subject may not receive study vaccine until at least 50 days after the transplant procedure).
  • (HIV) infection by clinical history.
  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period. However, the investigational use of a registered product to treat the subject's underlying disease, is allowed.
  • Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.
  • Planned administration during the study of a HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • Occurrence of a varicella or HZ episode by clinical history within the 12 months preceding the first dose of study vaccine/placebo.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine.
  • Administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions before Month 3 (i.e., 2 months after the last dose of study vaccine/placebo).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
568 participants (actual)

Study arms

  • Experimental
    Vaccine Group

    Subjects will receive the candidate HZ vaccine (GSK 1437173A).

    Biological: Herpes zoster vaccine (GSK 1437173A)

  • Placebo comparator
    Placebo Group

    Subjects will receive the placebo vaccine.

    Drug: Placebo

Interventions

  • 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

  • DrugPlacebo

    2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

06

What researchers measure

Primary outcomes

  1. Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations

    Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (≥) 4 fold the cut-off for Anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]. For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre-vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.

    Time frame: At Month 2

  2. Adjusted Geometric Mean Concentration of Anti-gE Antibodies

    The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.

    Time frame: At Month 2

  3. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  4. Number of Days With Solicited Local Symptoms

    Solicited local symptoms: pain, redness, swelling and their number of days were recorded after each vaccination dose.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period

  5. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic route measured temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  6. Number of Days With Solicited General Symptoms

    Solicited general symptoms: fatigue, gastrointestinal symptoms, headache, myalgia, shivering, temperature and their number of days were recorded after each vaccination dose.

    Time frame: Withing the 7-day (Day 0-6) post-vaccination period

  7. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study. It also included any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within the 30-day (Days 0-29) post-vaccination period

  8. Number of Subjects With Serious Adverse Events (SAEs)

    A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination

    Time frame: From first vaccination up to 30 days post last vaccination

  9. Number of Subjects Reporting Any and Related Potential Immune-mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination

    Time frame: From first vaccination up to 30 days post last vaccination

Secondary outcomes

  1. Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations

    Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.

    Time frame: At Month 2

  2. Anti-gE Antibody Concentrations

    Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).This parameter was assessed in subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.

    Time frame: At Month 2

  3. Time to Occurrence of Any Confirmed HZ Case

    Time to occurrence of any confirmed HZ case is expressed in terms of incidence rate of subjects with at least one event. Hence, person-year rate = number of episodes (n)/ sum of follow-up period (censored at the first occurrence of an event) expressed in years (T\[year)\]). Follow-up period starts Day 1 of vaccination. Any clinically suspected case of HZ (defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings suggestive of VZV infection in the absence of characteristic HZ or VZV rash.) The endpoint is confirmed in two ways: (1) By Polymerase Chain Reaction (PCR) or (2) By the HZ Ascertainment Committee. The PCR is used as primary classification method.

    Time frame: From Month 0 until study end (Month 13)

  4. Anti-gE Antibody Concentrations

    Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). This parameter was assessed in all vaccinated subjects.

    Time frame: At Months 0, 1, 2 and 13

  5. Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations

    Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. Vaccine response was measured in all subjects.

    Time frame: At Months 1, 2 and 13

  6. Frequency of gE -Specific Cluster of Differentiation 4 (CD4) [2+] T-cells Expressing at Least 2 Activation Markers

    Among markers expressed were interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 ligand (CD40L), as determined by in vitro intracellular cytokine staining (ICS).

    Time frame: At Months 0, 1, 2 and 13

  7. Vaccine Response Rates (VRR) for gE-specific CD4 [2+] T-cells, Expressing at Least 2 Activation Markers

    Among markers expressed were IFN-γ, IL-2, TNF-α and CD40L, as determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/106 CD4+ T cells). For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

    Time frame: At Months 1, 2 and 13

  8. Number of Subjects With Serious Adverse Events (SAEs)

    A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination

    Time frame: From first vaccination at Month 0 up to study end at Month 13

  9. Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

    Time frame: From first vaccination at Month 0 up to study end at Month 13

  10. Geometric Mean Concentrations (GMCs) of Anti-gE Antibodies

    GMCs of anti-gE antibodies were tabulated per study group and HZ confirmed/non-confirmed status and expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 0 and 2

  11. Mean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations

    MGI was tabulated per study group and HZ confirmed/non-confirmed status. MGI was defined as the Geometric mean of the within subject ratios of the post-vaccination reciprocal anti-gE concentration to the Month 0 reciprocal anti-gE concentration.

    Time frame: At Month 2

07

Results

Posted May 25, 2017

Participant flow

Vaccination Phase (up to Month 2)
Participant flow — Vaccination Phase (up to Month 2)
MilestoneGSK1437173A GroupPlacebo Group
Started283279
Completed266259
Not completed1720
Withdrew: Adverse event88
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject710
Withdrew: Suspected herpes zoster episode01
Withdrew: Physician decision10
Withdrew: Subject unavailable01
End of Study Phase (up to Month 13)
Participant flow — End of Study Phase (up to Month 13)
MilestoneGSK1437173A GroupPlacebo Group
Started283279
Completed236216
Not completed4763
Withdrew: Adverse event2939
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject914
Withdrew: Migrated/moved from study area03
Withdrew: Lost to follow-up64
Withdrew: Suspected herpes zoster episode01
Withdrew: Physician decision10
Withdrew: Subject unavailable02

Outcome measures

PrimaryVaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations

Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 greater than or equal to (≥) 4 fold the cut-off for Anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]. For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre-vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.

Time frame:
At Month 2
Reported as:
Number · Percentage
Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations
PercentageGSK1437173A GroupPlacebo Group
Vaccine Response Rates (VRR) for Anti-glycoprotein E (Anti-gE) Antibody Concentrations80.4 (73.1 to 86.5)0.8 (0.0 to 4.2)
PrimaryAdjusted Geometric Mean Concentration of Anti-gE Antibodies

The Adjusted geometric mean concentration was measured in all subjects excluding those with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia.

Time frame:
At Month 2
Reported as:
Geometric mean · mIU/mL
Adjusted Geometric Mean Concentration of Anti-gE Antibodies
mIU/mLGSK1437173A GroupPlacebo Group
Adjusted Geometric Mean Concentration of Anti-gE Antibodies22132.9 (16642.8 to 32153.9)777.6 (702.8 to 860.3)
Statistical analysis
  • GSK1437173A Group vs Placebo Group · Repeated measurement model · p = <0.0001 (The p-value is relative to the null hypothesis Ho: Vaccine / Placebo = 1) · Adjusted geometric mean concentration: 29.75 · 95% CI 21.09 to 41.96
PrimaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Pain, Dose 119926
Grade 3 Pain, Dose 1160
Any Redness, Dose 1801
Grade 3 Redness, Dose 120
Any Swelling, Dose 1472
Grade 3 Swelling, Dose 110
Any Pain, Dose 217231
Grade 3 Pain, Dose 2200
Any Redness, Dose 2825
Grade 3 Redness, Dose 2100
Any Swelling, Dose 2421
Grade 3 Swelling, Dose 250
Any Pain, Across doses22145
Grade 3 Pain, Across doses290
Any Redness, Across doses1155
Grade 3 Redness, Across doses120
Any Swelling, Across doses632
Grade 3 Swelling, Across doses50
PrimaryNumber of Days With Solicited Local Symptoms

Solicited local symptoms: pain, redness, swelling and their number of days were recorded after each vaccination dose.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms
DaysGSK1437173A GroupPlacebo Group
Pain, Dose 13.0 (2.0 to 4.0)1.0 (1.0 to 2.0)
Pain, Dose 23.0 (2.0 to 4.0)2.0 (1.0 to 3.0)
Redness, Dose 13.0 (2.0 to 5.0)1.0 (1.0 to 1.0)
Redness, Dose 23.0 (2.0 to 5.0)4.0 (2.0 to 6.0)
Swelling, Dose 13.0 (2.0 to 4.0)1.5 (1.0 to 2.0)
Swelling, Dose 23.0 (2.0 to 4.0)4.0 (4.0 to 4.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic route measured temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any fatigue, Dose 112273
Grade 3 fatigue, Dose 1118
Related fatigue, Dose 13711
Any gastrointestinal, Dose 14824
Grade 3 gastrointestinal, Dose 152
Related gastrointestinal, Dose 1131
Any headache, Dose 17040
Grade 3 headache, Dose 133
Related headache, Dose 12910
Any myalgia, Dose 18035
Grade 3 myalgia, Dose 1110
Related myalgia, Dose 13310
Any shivering, Dose 13916
Grade 3 shivering, Dose 120
Related shivering, Dose 1142
Any temperature, Dose 13315
Grade 3 temperature, Dose 101
Related temperature, Dose 1183
Any fatigue, Dose 212667
Grade 3 fatigue, Dose 2166
Related fatigue, Dose 24913
Any gastrointestinal, Dose 25316
Grade 3 gastrointestinal, Dose 252
Related gastrointestinal, Dose 2204
Any headache, Dose 29042
Grade 3 headache, Dose 2103
Related headache, Dose 2429
Any myalgia, Dose 29325
Grade 3 myalgia, Dose 2145
Related myalgia, Dose 2507
Any shivering, Dose 2487
Grade 3 shivering, Dose 290
Related shivering, Dose 2271
Any temperature, Dose 25111
Grade 3 teamperature, Dose 230
Related temperature, Dose 2283
Any fatigue, Across doses162102
Grade 3 fatigue, Across doses2310
Related fatigue, Across doses6322
Any gastrointestinal, Across doses7629
Grade 3 gastrointestinal, Across doses93
Related gastrointestinal, Across doses285
Any headache, Across doses11564
Grade 3 headache, Across doses126
Related headache, Across doses5216
Any myalgia, Across doses12248
Grade 3 myalgia, Across doses225
Related myalgia, Across doses6315
Any shivering, Across doses6918
Grade 3 shivering, Across doses110
Related shivering, Across doses362
Any temperature, Across doses6821
Grade 3 temperature, Across doses31
Related teamperature, Across doses364
PrimaryNumber of Days With Solicited General Symptoms

Solicited general symptoms: fatigue, gastrointestinal symptoms, headache, myalgia, shivering, temperature and their number of days were recorded after each vaccination dose.

Time frame:
Withing the 7-day (Day 0-6) post-vaccination period
Reported as:
Median · Days
Number of Days With Solicited General Symptoms
DaysGSK1437173A GroupPlacebo Group
Fatigue, Dose 13.0 (1.0 to 6.0)3.0 (2.0 to 7.0)
Fatigue, Dose 23.0 (2.0 to 5.0)3.0 (1.0 to 7.0)
Gastrointestinal symptoms, Dose 12.5 (1.0 to 5.0)3.5 (1.5 to 6.0)
Gastrointestinal symptoms, Dose 22.0 (1.0 to 3.0)6.0 (2.5 to 7.0)
Headache, Dose 12.0 (1.0 to 3.0)1.5 (1.0 to 3.0)
Headache, Dose 22.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Myalgia, Dose 13.5 (2.0 to 5.5)3.0 (1.0 to 4.0)
Myalgia, Dose 22.0 (2.0 to 4.0)3.0 (1.0 to 7.0)
Shivering, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.5)
Shivering, Dose 21.0 (1.0 to 2.0)4.0 (2.0 to 4.0)
Temperature, Dose 11.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Temperature, Dose 21.0 (1.0 to 2.0)2.0 (1.0 to 4.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study. It also included any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any AEs134128
Grade 3 AEs2528
Related AEs195
PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination

Time frame:
From first vaccination up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
At least one SAE1729
Related SAEs00
PrimaryNumber of Subjects Reporting Any and Related Potential Immune-mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMds assessed by the investigator as causally related to the study vaccination

Time frame:
From first vaccination up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any and Related Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Any pIMDs10
Related pIMDs00
SecondaryVaccine Response Rate (VRR) for Anti-gE Antibody Concentrations

Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. This analysis was performed on subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.

Time frame:
At Month 2
Reported as:
Number · Percentage
Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations
PercentageGSK1437173A GroupPlacebo Group
Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations69.0 (61.8 to 75.6)0.6 (0.0 to 3.3)
SecondaryAnti-gE Antibody Concentrations

Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).This parameter was assessed in subjects with haematologic malignancies, excluding subjects with Non-Hodgkin B-cell Lymphoma.

Time frame:
At Month 2
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
Anti-gE Antibody Concentrations15795.5 (11603.3 to 21502.2)791.6 (648.9 to 965.5)
SecondaryTime to Occurrence of Any Confirmed HZ Case

Time to occurrence of any confirmed HZ case is expressed in terms of incidence rate of subjects with at least one event. Hence, person-year rate = number of episodes (n)/ sum of follow-up period (censored at the first occurrence of an event) expressed in years (T\[year)\]). Follow-up period starts Day 1 of vaccination. Any clinically suspected case of HZ (defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings suggestive of VZV infection in the absence of characteristic HZ or VZV rash.) The endpoint is confirmed in two ways: (1) By Polymerase Chain Reaction (PCR) or (2) By the HZ Ascertainment Committee. The PCR is used as primary classification method.

Time frame:
From Month 0 until study end (Month 13)
Reported as:
Number · Person-year rate
Time to Occurrence of Any Confirmed HZ Case
Person-year rateGSK1437173A GroupPlacebo Group
Time to Occurrence of Any Confirmed HZ Case0.020 (0.009 to 0.045)0.071 (0.045 to 0.111)
SecondaryAnti-gE Antibody Concentrations

Antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). This parameter was assessed in all vaccinated subjects.

Time frame:
At Months 0, 1, 2 and 13
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
Anti-gE, Month 0964.0 (814.5 to 1140.8)883.7 (749.9 to 1041.4)
Anti-gE, Month 14216.5 (3328.6 to 5341.4)824.2 (699.4 to 971.3)
Anti-gE, Month 213445.6 (10158.9 to 17795.6)832.0 (701.1 to 987.3)
Anti-gE, Month 135202.7 (4074.8 to 6642.8)895.4 (734.5 to 1091.5)
SecondaryVaccine Response Rate (VRR) for Anti-gE Antibody Concentrations

Vaccine response rate refers to the percentage of subjects with a vaccine response, as determined by ELISA. Vaccine response was defined as: For initially seronegative subjects, antibody concentration at Month 2 ≥ 4 fold the cut-off for anti-gE (4x97 mIU/mL). For initially seropositive subjects, antibody concentration at Month 2 ≥ 4 fold the pre -vaccination antibody concentration. Vaccine response was measured in all subjects.

Time frame:
At Months 1, 2 and 13
Reported as:
Number · Percentage
Vaccine Response Rate (VRR) for Anti-gE Antibody Concentrations
PercentageGSK1437173A GroupPlacebo Group
VRR, anti-gE, Month 144.2 (37.4 to 51.1)0.0 (0.0 to 1.9)
VRR, anti-gE, Month 265.4 (58.7 to 71.7)0.5 (0.0 to 2.8)
VRR, anti-gE, Month 1352.1 (44.2 to 59.9)3.6 (1.2 to 8.1)
SecondaryFrequency of gE -Specific Cluster of Differentiation 4 (CD4) [2+] T-cells Expressing at Least 2 Activation Markers

Among markers expressed were interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 ligand (CD40L), as determined by in vitro intracellular cytokine staining (ICS).

Time frame:
At Months 0, 1, 2 and 13
Reported as:
Mean · CD4 [2+] T-cells/million T-cells
Frequency of gE -Specific Cluster of Differentiation 4 (CD4) [2+] T-cells Expressing at Least 2 Activation Markers
CD4 [2+] T-cells/million T-cellsGSK1437173A GroupPlacebo Group
CD4 [2+], Month 0226.78 ± 659.84147.30 ± 191.91
CD4 [2+], Month 11261.67 ± 2318.36196.74 ± 332.52
CD4 [2+], Month 26083.98 ± 10467.57318.20 ± 1000.90
CD4 [2+], Month 133626.87 ± 7758.18181.23 ± 387.90
SecondaryVaccine Response Rates (VRR) for gE-specific CD4 [2+] T-cells, Expressing at Least 2 Activation Markers

Among markers expressed were IFN-γ, IL-2, TNF-α and CD40L, as determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/106 CD4+ T cells). For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

Time frame:
At Months 1, 2 and 13
Reported as:
Number · Percentage
Vaccine Response Rates (VRR) for gE-specific CD4 [2+] T-cells, Expressing at Least 2 Activation Markers
PercentageGSK1437173A GroupPlacebo Group
CD4 [2+], Month 137.5 (24.0 to 52.6)2.1 (0.1 to 11.3)
CD4 [2+], Month 283.7 (69.3 to 93.2)6.8 (1.4 to 18.7)
CD4 [2+], Month 1366.7 (48.2 to 82.0)6.5 (0.8 to 21.4)
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

A Serious adverse event (SAE) is any untoward medical occurrence that result in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. Related = SAEs assessed by the investigator as causally related to the study vaccination

Time frame:
From first vaccination at Month 0 up to study end at Month 13
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
At least one SAE, up to Month 65060
Related SAEs, up to Month 601
At least one SAE, up to Month 136682
Related SAEs, up to Month 1311
SecondaryNumber of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

Time frame:
From first vaccination at Month 0 up to study end at Month 13
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Up to Month 631
Up to Month 1332
SecondaryGeometric Mean Concentrations (GMCs) of Anti-gE Antibodies

GMCs of anti-gE antibodies were tabulated per study group and HZ confirmed/non-confirmed status and expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 0 and 2
Reported as:
Geometric mean · mIU/ml
Geometric Mean Concentrations (GMCs) of Anti-gE Antibodies
mIU/mlGSK1437173A HZ Cases Sub-GroupGSK1437173A Non-HZ Cases Sub-GroupPlacebo HZ Cases Sub-GroupPlacebo Non-HZ Cases Sub-Group
PRE115.9 (0.0 to 7406196)973.6 (835.6 to 1134.4)984.5 (500.7 to 1935.7)866.3 (745.5 to 1006.6)
Month 2184.0 (0.0 to 4187800000)12517.4 (9662.0 to 16216.6)960.5 (454.2 to 2031.1)802.9 (686.7 to 938.9)
SecondaryMean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations

MGI was tabulated per study group and HZ confirmed/non-confirmed status. MGI was defined as the Geometric mean of the within subject ratios of the post-vaccination reciprocal anti-gE concentration to the Month 0 reciprocal anti-gE concentration.

Time frame:
At Month 2
Reported as:
Geometric mean · Ratio
Mean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations
RatioGSK1437173A HZ Cases Sub-GroupGSK1437173A Non-HZ Cases Sub-GroupPlacebo HZ Cases Sub-GroupPlacebo Non-HZ Cases Sub-Group
Mean Geometric Increase (MGI) of Anti-gE Antibody ELISA Concentrations1.59 (0.00 to 565.45)13.07 (9.93 to 17.22)0.98 (0.80 to 1.19)0.94 (0.88 to 1.00)

Adverse events

Collected over Solicited and unsolicited symptoms: within the 30-day (Days 0-29) post-vaccination period; SAEs: up to study end, at Month 13.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group29/283 (10.2%)66/283 (23.3%)252/283 (89%)
Placebo Group37/279 (13.3%)82/279 (29.4%)146/279 (52.3%)
Most frequent serious events
Showing 10 of 188
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
Febrile neutropeniaBlood and lymphatic system disorders14/28311/279
PneumoniaInfections and infestations11/28311/279
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2838/279
SepsisInfections and infestations5/2836/279
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2836/279
Acute kidney injuryRenal and urinary disorders5/2834/279
ThrombocytopeniaBlood and lymphatic system disorders4/2831/279
PyrexiaGeneral disorders3/2833/279
Septic shockInfections and infestations3/2833/279
NeutropeniaBlood and lymphatic system disorders3/2832/279
Most frequent other events
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders221/28346/279
FatigueGeneral disorders163/283102/279
MyalgiaMusculoskeletal and connective tissue disorders123/28348/279
ErythemaSkin and subcutaneous tissue disorders116/2836/279
HeadacheNervous system disorders115/28365/279
Gastrointestinal disorderGastrointestinal disorders76/28329/279
PyrexiaGeneral disorders74/28324/279
ChillsGeneral disorders69/28319/279
SwellingGeneral disorders63/2832/279

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupPlacebo GroupTotal
Mean56.8 ± 15.557.8 ± 14.957.3 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupPlacebo GroupTotal
Female114114228
Male169165334
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupPlacebo GroupTotal
Geographic ancestry — African Heritage / African American112
Geographic ancestry — American Indian or Alaskan Native011
Geographic ancestry — Asian - Central / South Asian Heritage5611
Geographic ancestry — Asian - East Asian Heritage5760117
Geographic ancestry — Asian - South East Asian Heritage415
Geographic ancestry — White - Arabic / North African Heritage011
Geographic ancestry — White - Caucasian / European Heritage198186384
Geographic ancestry — Other71219
Geographic ancestry — Missing111122
08

Study locations

86 sites
  • GSK Investigational Site
    Inverness, Florida 34452, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Elkhart, Indiana 46514, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Seattle, Washington 98108, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Hobart, Tasmania 7000, Australia
  • GSK Investigational Site
    Coburg, Victoria 3058, Australia
  • GSK Investigational Site
    Wodonga, Victoria 3690, Australia
  • GSK Investigational Site
    Antwerpen, 2060, Belgium
  • GSK Investigational Site
    Brugge, 8000, Belgium
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Hasselt, 3500, Belgium
  • GSK Investigational Site
    Jette, 1090, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Saint John, New Brunswick E2L 4L2, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1G 2B9, Canada
  • GSK Investigational Site
    Toronto, Ontario M4C 3E7, Canada
  • GSK Investigational Site
    Praha 2, 128 08, Czechia
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Mulhouse, 68070, France
  • GSK Investigational Site
    Nantes cedex 1, 44093, France
  • GSK Investigational Site
    Pessac cedex, 33604, France
  • GSK Investigational Site
    Périgueux cedex, 24019, France
  • GSK Investigational Site
    Rouen cedex 1, 76038, France
  • GSK Investigational Site
    Hong Kong, Hong Kong
  • GSK Investigational Site
    Meldola (FC), Emilia-Romagna 47014, Italy
  • GSK Investigational Site
    Udine, Friuli-Venezia-Giulia 33100, Italy
  • GSK Investigational Site
    Novara, Piemonte 28100, Italy
  • GSK Investigational Site
    Busan, 614-735, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-721, Korea, Republic of
  • GSK Investigational Site
    Incheon, 405-760, Korea, Republic of
  • GSK Investigational Site
    Jellanamdo, 519-809, Korea, Republic of
  • GSK Investigational Site
    Jeonju, 561-712, Korea, Republic of
  • GSK Investigational Site
    Kyunggi-do, 410-769, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Christchurch, 8011, New Zealand
  • GSK Investigational Site
    Hamilton, 3240, New Zealand
  • GSK Investigational Site
    Lahore, Pakistan
  • GSK Investigational Site
    Multan, Pakistan
  • GSK Investigational Site
    Panama, Panama
  • GSK Investigational Site
    Chorzow, 41-500, Poland
  • GSK Investigational Site
    Opole, 45-372, Poland
  • GSK Investigational Site
    Slupsk, 76-200, Poland
  • GSK Investigational Site
    Ekaterinburg, 620102, Russian Federation
  • GSK Investigational Site
    Nizhniy Novgorod, 603126, Russian Federation
  • GSK Investigational Site
    Petrozavodsk, 185019, Russian Federation
  • GSK Investigational Site
    St'Petersburg, 191024, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 197758, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197 089, Russian Federation
  • GSK Investigational Site
    Singapore, 169608, Singapore
  • GSK Investigational Site
    Móstoles, Madrid 28933, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28009, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Majadahonda (Madrid), 28222, Spain
  • GSK Investigational Site
    Pozuelo De Alarcón/Madrid, 28223, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Eskilstuna, SE-631 88, Sweden
  • GSK Investigational Site
    Karlskrona, SE-371 41, Sweden
  • GSK Investigational Site
    Malmö, SE-205 02, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
  • GSK Investigational Site
    Kaohsiung, 833, Taiwan
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Taipei, 112, Taiwan
  • GSK Investigational Site
    Taoyuan Hsien, 333, Taiwan
  • GSK Investigational Site
    Ankara, 06500, Turkey
  • GSK Investigational Site
    Ankara, 06590, Turkey
  • GSK Investigational Site
    Orpington, Kent BR6 8ND, United Kingdom
  • GSK Investigational Site
    Airdrie, Lanarkshire ML6 0JS, United Kingdom
  • GSK Investigational Site
    Swindon, Wiltshire SN3 6BB, United Kingdom
  • GSK Investigational Site
    Bournemouth, BH7 7DW, United Kingdom
  • GSK Investigational Site
    Headington, Oxford, OX3 7LE, United Kingdom
  • GSK Investigational Site
    London, SE13 6LH, United Kingdom
09

References and documents

Publications

  • Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macias G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, Lopez-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Erratum In: Lancet Infect Dis. 2020 Jan;20(1):e1. doi: 10.1016/S1473-3099(19)30671-1. PubMed 31399377 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jan 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2013
First posted
Jan 14, 2013
Start
Mar 1, 2013
Primary completionActual
Jan 7, 2016
CompletionActual
Jan 6, 2017
Results first posted
May 25, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01767467
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Mar 1, 2013
Primary completion
Jan 7, 2016
Completion
Jan 6, 2017
Results posted
May 25, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Herpes Zoster Vaccine

Start the discussion